Bladder Preservation in Octogenarians With Invasive Bladder Cancer

被引:14
|
作者
Wehrberger, Clemens [1 ]
Berger, Ingrid [1 ]
Marszalek, Martin [1 ]
Ponholzer, Anton [1 ]
Wehrberger, Marlies [1 ]
Rauchenwald, Michael [1 ]
Madersbacher, Stephan [1 ]
机构
[1] Donauspital, Dept Urol & Androl, A-1220 Vienna, Austria
关键词
RADICAL CYSTECTOMY; TRANSURETHRAL RESECTION; ELDERLY-PATIENTS; CARCINOMA; SURVIVAL; EXPERIENCE; MORTALITY; YOUNGER;
D O I
10.1016/j.urology.2009.10.027
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES To analyze mortality and morbidity of octogenarians with newly diagnosed invasive transitional cell cancer (TCC) of the bladder who were managed without cystectomy. METHODS Retrospective chart review of all patients with newly diagnosed invasive TCC (>= pT1) in the period of 1997-2007, who were 80 years or older at diagnosis. RESULTS A total of 71 patients (86 + 4 years, mean + standard deviation [SD], pT1: n = 29; >pT2: n = 42) entered this analysis. In this geriatric population, treatment regimens were highly individualized. After transurethral resection, 61% of pT1-patients received bacillus Calmette-Guerin and 62% of those with >pT2-tumors external beam radiation. Mean overall survival (OS) of the entire cohort (n = 71) was 22 + 26 months for pT1-patients 34 + 33 versus 14 + 15 months for those with >pT2-tumors (P = .001). Mean cancer-specific survival was 58 months for pT1-patients and 11 months for >= pT2-patients (P < .001). OS was correlated to tumor stage and the degree of mobility, to a lesser extent to the American Society of Anesthesiologists (ASA) score, and only marginally to chronologic age. Satisfactorily bladder function was preserved in 73%. pT1-patients spent 16% of their remaining life-span in the hospital compared with 23% for patients with >pT2-tumors. CONCLUSIONS OS in TCC is dependent on tumor stage, age, mobility, and comorbidities, and a risk-stratified management is necessary. Patients with pT1G3 tumor and low ASA score have satisfying OS with bladder preservation, but in patients with >= pT2 and ASA 3-4 the prognosis is very bad. It remains questionable whether patients with tumor stages >= pT2 and ASA 1-2 despite high age would benefit from radical cystectomy. UROLOGY 75: 370-375, 2010. (C) 2010 Elsevier Inc.
引用
收藏
页码:370 / 375
页数:6
相关论文
共 50 条
  • [21] Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer
    Miyamoto, David T.
    Mouw, Kent W.
    Feng, Felix Y.
    Shipley, William U.
    Efstathiou, Jason A.
    LANCET ONCOLOGY, 2018, 19 (12) : E683 - E695
  • [22] Exploring Texture Analysis to Optimize Bladder Preservation in Muscle Invasive Bladder Cancer
    Mehta, Prachi
    Sinha, Shwetabh
    Kashid, Sheetal
    Chakraborty, Debanjan
    Mhatre, Ritesh
    Murthy, Vedang
    CLINICAL GENITOURINARY CANCER, 2022, 21 (03) : E138 - E144
  • [23] Current State of Bladder Preservation in High Grade Non-Muscle Invasive Bladder Cancer and Localized Muscle Invasive Bladder Cancer
    Popli, Swati
    Durant, Adri M.
    Tyson, Mark
    Singh, Parminder
    CURRENT ONCOLOGY REPORTS, 2025,
  • [24] BLADDER PRESERVATION WITH IMAGE-GUIDED RADIOTHERAPY FOR ELDERLY PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER: A SINGLE INSTUTION EXPERIENCE
    Aynaci, Ozlem
    Serdar, Lasif
    Zengin, Ahmet Yasar
    Savli, Evrim
    Uslu, Gonca Hanedan
    Gedik, Sonay
    TURKISH JOURNAL OF GERIATRICS-TURK GERIATRI DERGISI, 2021, 24 (02): : 174 - 184
  • [25] Impact of sarcopenia in bladder preservation therapy for muscle-invasive bladder cancer patients: a narrative review
    Fukushima, Hiroshi
    Koga, Fumitaka
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2022, : 1433 - 1441
  • [26] The Role of Maximal TURBT in Muscle-Invasive Bladder Cancer: Balancing Benefits in Bladder Preservation and Beyond
    Moghaddam, Farshad Sheybaee
    Dwabe, Sami
    Mar, Nataliya
    Safdari, Leila
    Sabharwal, Navin
    Goldberg, Hanan
    Daneshvar, Michael
    Rezazadeh Kalebasty, Arash
    CANCERS, 2024, 16 (19)
  • [27] Primary Bladder Preservation Treatment for Urothelial Bladder Cancer
    Biagioli, Matthew C.
    Fernandez, Daniel C.
    Spiess, Philippe E.
    Wilder, Richard B.
    CANCER CONTROL, 2013, 20 (03) : 188 - 199
  • [28] Chemoradiation for organ preservation in the treatment of muscle-invasive bladder cancer
    McHaffie, Derek R.
    Kruser, Tim J.
    Gaston, Kris
    Mahoney, John
    Graham, David
    Haake, Michael
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2016, 34 (06) : 271 - 278
  • [29] The Role of Neoadjuvant Chemotherapy in Bladder Preservation Approaches in Muscle-Invasive Bladder Cancer
    Stecca, Carlos
    Mitin, Timur
    Sridhar, Srikala S.
    SEMINARS IN RADIATION ONCOLOGY, 2023, 33 (01) : 51 - 55
  • [30] Unconventional Bladder Preservation: Factors Predicting Failure to Receive Definitive Surgery following Chemotherapy for Nonmetastatic Muscle Invasive Bladder Cancer in the National Cancer Database
    Kapadia, Akash A.
    Acevedo, Ann Martinez
    Liu, Jen-Jane
    Garzotto, Mark
    Conlin, Michael
    Amling, Christopher
    Kopp, Ryan P.
    JOURNAL OF UROLOGY, 2018, 200 (03) : 535 - 539